Corcept Therapeutics Presents SYNERGY Trial Data Combining Nenocorilant With Immunotherapy
The California-based biotech disclosed results from a Phase 1b/2 study evaluating its glucocorticoid receptor antagonist in combination with Bristol Myers Squibb's Nivolumab for advanced solid tumors.
SYNERGY Trial Results Disclosed
Corcept Therapeutics Incorporated (NASDAQ: CORT) announced results from the SYNERGY study, a Phase 1b/2 clinical trial evaluating nenocorilant in combination with nivolumab for patients with advanced solid malignancies. The data, presented by Hamid et al. at the 2026 American Society of Clinical Oncology (ASCO) conference, represents a continued expansion of the company's oncology pipeline beyond its core Cushing's syndrome franchise.
Nenocorilant is a selective glucocorticoid receptor antagonist, a mechanism the company has positioned as potentially complementary to checkpoint inhibitors like nivolumab, Bristol Myers Squibb's anti-PD-1 immunotherapy. The SYNERGY trial design sought to assess the safety and preliminary efficacy of this combination approach in patients with advanced solid tumors.
Beyond Cushing's Syndrome
Corcept, which commands a market capitalization of approximately $13 billion with shares closing at $118.32, has built its commercial foundation on mifepristone for Cushing's syndrome. The company's efforts to broaden its glucocorticoid receptor modulator platform into oncology represent a significant strategic expansion, with nenocorilant serving as a key investigational asset in this effort.
The rationale for combining glucocorticoid receptor antagonism with immunotherapy stems from research suggesting that glucocorticoid signaling may contribute to immunosuppression in the tumor microenvironment, potentially limiting the effectiveness of checkpoint inhibitors.
Looking Ahead
According to MarginX data, Corcept is expected to report third-quarter 2026 results on November 4, 2026, which may provide additional commentary on the company's oncology development strategy. Recent insider activity shows options exercises and stock sales by Atabak Mokari, including the exercise of 24,167 shares and 15,833 shares, followed by a sale of 28,460 shares.
The broader market context includes upcoming Federal Reserve rate decisions on September 16 and October 28, 2026, which could influence investor appetite for growth-oriented biotech equities.
This article was generated by MarginX from public news on 2026-07-30. It is not investment advice.